Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Convertible Debt (2016 - 2023)

Historic Convertible Debt for Protalix BioTherapeutics (PLX) over the last 11 years, with Q4 2023 value amounting to $20.4 million.

  • Protalix BioTherapeutics' Convertible Debt fell 2755.53% to $20.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $20.4 million, marking a year-over-year decrease of 2755.53%. This contributed to the annual value of $20.4 million for FY2023, which is 2755.53% down from last year.
  • As of Q4 2023, Protalix BioTherapeutics' Convertible Debt stood at $20.4 million, which was down 2755.53% from $20.1 million recorded in Q2 2023.
  • Over the past 5 years, Protalix BioTherapeutics' Convertible Debt peaked at $53.5 million during Q3 2020, and registered a low of $20.1 million during Q2 2023.
  • Its 5-year average for Convertible Debt is $37.1 million, with a median of $28.2 million in 2022.
  • Its Convertible Debt has fluctuated over the past 5 years, first skyrocketed by 666.23% in 2020, then crashed by 4801.23% in 2021.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Convertible Debt stood at $51.0 million in 2019, then increased by 5.0% to $53.5 million in 2020, then tumbled by 47.88% to $27.9 million in 2021, then increased by 1.08% to $28.2 million in 2022, then fell by 27.56% to $20.4 million in 2023.
  • Its last three reported values are $20.4 million in Q4 2023, $20.1 million for Q2 2023, and $28.3 million during Q1 2023.